Phase 1, Open-Label, Dose Escalation Study of Anti-CD98 Monoclonal Antibody KHK2898 as Monotherapy in Subjects With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy Is Available

Next Previous
Trial Profile

Phase 1, Open-Label, Dose Escalation Study of Anti-CD98 Monoclonal Antibody KHK2898 as Monotherapy in Subjects With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy Is Available

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs KHK 2898 (Primary)
  • Indications Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Kyowa Hakko Kirin

    • Most Recent Events

    • 14 Mar 2017 Status changed from completed to discontinued.
    • 09 Mar 2017 Status changed from not yet recruiting to completed.
    • 22 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top